CD8A and neoplasm: Furthermore, in an immunocompetent mouse model of syngeneic B-cell lymphoma, CD19-CAR-iNKT cells exerted potent direct cancer cell killing and were also able to recruit host tumor-specific CD8 T-cell responses via facilitating tumor-antigen cross-priming, in turn enhancing long term cancer control (134).